Enumeral Biomedical Holdings Inc

Enumeral Biomedical — Investor Presentation (April 2015)

25 slides from Enumeral Biomedical's investor presentation, Apr 28, 2015

  1. Slide 1: The Power of Human

    THE POWER of HUMAN™ April 2015

  2. Slide 2: Forward Looking Statements

    Forward Looking S tatements OTC QB: ENUM THIS PRESENTATION CONTAINS FORWARD - LOOKING STATEMENTS THAT ARE BASED ON THE COMPANY’S CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS ABOUT THE COMPANY AND THE PHARMACEUTICAL INDUSTRY. THE COMPANY MAKES NO REPRESENTATIONS ABOUT THE ACCURACY OF

  3. Slide 3: Enumeral Overview

    Enumeral Overview 3 Pioneering ‘Human immune system on a chip’ platform that uniquely leverages human cell biology Highly productive and broadly enabling R&D engine Multiple antibody immunotherapies progressing toward the clinic • Technology licensed exclusively from MIT, Harvard • Application valid

  4. Slide 4: Experienced Leadership Team

    Experienced Leadership T eam 4 John J. Rydzewski Executive Chairman, Co - Founder, Director Arthur H. Tinkelenberg, Ph.D. President & CEO, Co - Founder, Director Kevin G. Sarney Vice President, Finance, & Chief Accounting Officer Isabel Chiu, Ph.D. Vice President, Translational & Clinical Sciences C

  5. Slide 5: Accomplished Board of Directors

    Accomplished Board of Directors 5 John J. Rydzewski Executive Chairman, Co - Founder, Director Arthur H. Tinkelenberg, Ph.D. President & CEO, Co - Founder, Director Barry Buckland, Ph.D. Co - Founder, Co - Chairman, Scientific Advisory Board Allan Rothstein Director Paul J. Sekhri Director Robert L.

  6. Slide 6: Enumeral's Rapidly Advancing Pipeline

    6 Enumeral’s Rapidly A dvancing P ipeline 2015 2016 2017 Target Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 PD - 1 Tim3 Lag - 3 OX40 VISTA Undisclosed Screening Screening Screening Screening Preclinical Efficacy Preclinical Efficacy Preclinical Efficacy Preclinical Efficacy Preclinical Efficacy IND Enabling St

  7. Slide 7: Strong Near-Term Growth Potential Value

    S trong Near - Term G rowth P otential 7 V alue 2012 2013 2014 2015 2016 2017 Enumeral believes it is well - positioned to achieve significant value - generating milestones x NCI P hase 1 contract x $21.5M financing and public listing x NCI Phase 2 contract x Merck Collaboration x MSKCC and MGH coll

  8. Slide 8: Immunotherapy Market Opportunity

    Immunotherapy M arket O pportunity 8 *Citigroup **Bristol Myers Squibb Estimated cancer immunotherapy sales over next decade $35 billion per year (treating up to 60% of cancers*) Yervoy sales (launched in 2011) $1 billion in revenue (year ended June 20, 2014**) Strong interest in new approaches amon

  9. Slide 9: Breaking the Immuno-Oncology Code

    Breaking the “Immuno - Oncology C ode ” Proprietary ‘ human immune system on a chip ’ selects best - in - class antibodies and optimal target combinations 9 • Developing pipeline of antibody product candidates modulating Tumor - Infiltrating Lymphocyte (TIL) function • Next - generation checkpoint m

  10. Slide 10: Combinatorial Immunotherapy: The Next Frontier

    Combinatorial Immunotherapy ‘ The N ext Frontier’ • Combination therapies are necessary to drive higher response rates • Little to no data have to inform combinatorial development: – Combinations may yield unique toxicities – There are few biomarkers for complex indication subtypes – Microenvironmen

  11. Slide 11: Challenges in Immunotherapy Development

    Challenges in I mmunotherapy D evelopment 11 Immune cells are rare in human tissue samples → Difficult to enumerate with current technologies → Enumeral platform provides insights to solve these challenges Figure from Cancer Cell. 2014 Nov 10;26(5):623 - 37. Macrophage IL - 10 Blocks CD8(+) T Cell -

  12. Slide 12: Human is Better

    Human i s B etter Research models poorly predict human response to immunotherapies 12 Conventional Approach Enumeral’s Differentiated Approach Enumeral’s technology enables selection of potential best - in - class candidates using human cells from biopsies ?

  13. Slide 13: Enumeral's Broadly Enabling Platform

    Enumeral’s B roadly E nabling P latform 13 84,672 microwells • High - density bio - chip and one - day process • Measures key parameters of function of individual immune cells from patient samples • Uniquely enumerates and rapidly identifies rare immune cells critical to responses • Validates target

  14. Slide 14: Target Validation on TILs

    T arget Validation on TILs 14 Biopsy from colorectal cancer patient; No sorting or enrichment • Enables selection of antibodies targeting the correct cell types • Enables human immunologic annotation of the potential functional advantages of Enumeral’s antibodies early in the development process

  15. Slide 15: PD-1 Expressed on Many Cell Types Not Just T Cells

    PD - 1 Expressed on Many Cells Types Not J ust T Cells • Benefit of immune profiling in tandem with discovery is to identify cell types: – Involved in disease modulation – Selectively targeted by lead mAb candidates 15 Benson et al Blood 2010 NK cells in multiple myeloma patient expressing PD - 1 co

  16. Slide 16: Selecting Antibodies Based on Functional Properties

    Selecting Antibodies B ased on Functional P roperties : Effector C ell E ngagement 16 Hypothetical output of platform: Testing functional heterogeneity of antibodies* *Patent pending

  17. Slide 17: Functional Heterogeneity: Potential for Best-in-Class Differentiation

    Functional Heterogeneity: Potential for Best - in - Class P harmacologic and MOA Differentiation 17 Screen 1 - 12 Heavy chain AA sequences from PD1 N= 349 sequences; 28 families of antibodies BMY MRK MDVN • Enumeral proprietary antibody libraries • PD - 1: ~10 months - generation of unprecedented fu

  18. Slide 18: ENUM antibodies demonstrate pM affinity

    ENUM antibodies demonstrate pM affinity mAb EC 50 246A10 0.020 244C8 0.005 388D4 0.003 413E1 0.013 413D2 0.005 392C5 0.015 Keytruda 0.066 18 Several ENUM mAbs show superior EC 50 vs Keytruda (*Data Provided From Internal Enumeral Tests) 0 0.5 1 1.5 2 2.5 3 3.5 abs (405nm) mAb concentration (M) 388D4

  19. Slide 19: PD-L1 Suppression Assay

    PD - L1 Suppression A ssay 19 • PBMC - based assay to determine mAb’s ability to disrupt functional suppression by PD - L1 • ENUM candidates compared with : – Activation only – PD - L1 (suppression) – Positive control • ENUM A10 and C8 shown to reverse PD - L1 suppression more effectively than contr

  20. Slide 20: PD-1 Target Physiology Beyond Oncology

    PD - 1 Target Physiology: Potential to Solve Q uestions B ased on E x V ivo H uman P rofiling • Are psoriasis, inflammatory bowel disease, or rheumatoid arthritis T cell diseases? • Is the (presumed) IL - 17 or IFN g coming from pathologic T cells? • Is the disease etiology universal or variable acr

  21. Slide 21: Enumeral Programs and Goals

    Enumeral Programs and Goals • Advance first programs into ‘first in man’ testing by end of 2016 • Advance pipeline via platform insights : evaluating PD - 1 and Tim3 on human TILs in CRC cohorts for rational design of next - generation checkpoint modulators • Leverage platform to develop combination

  22. Slide 22: Recent Achievements

    Recent Achievements 22 July 2014 April 2015 December 2014 Raised $21.5M through private placement offering and began public trading on the OTC Markets ( OTCQB:ENUM) Appointments of veteran biotech executives to Board of Directors – • Paul J. Sekhri, President and Chief Executive Officer of Lycera Co

  23. Slide 23: Near-Term Corporate Objectives

    Near - Term Corporate Objectives • 2015: – Sign additional corporate partnerships – Achieve key human ex vivo preclinical milestone in lead program (PD - 1) – Commence IND - enabling studies in first program ( with a partner ) – Achieve key human ex vivo preclinical milestones on next programs – Com

  24. Slide 24: Financials & Capitalization

    THE POWER of HUMAN ™ Common Shares Outstanding 51,607,665 Warrants Outstanding* 24,803,409 Options Outstanding 2,730,963 Burn Rate , Q4 ’14 ($2.7M) Total Debt $0.0M Cash, Cash Equivalents and Marketable Securities** $13.5M 24 OTC QB: ENUM Price: $0.75 Market Cap (4/24/2015) $38.71M Enumeral: uniquel

  25. Slide 25: Contact

    THE POWER of HUMAN™ Arthur H. Tinkelenberg, Ph.D. President and CEO [email protected] 617 - 500 - 2647

Enumeral Biomedical Holdings — Investor Presentation (April 2015) on 6ix